Condition: Metastatic Colorectal Cancer · Sponsor: University of Wisconsin, Madison
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.
This description comes directly from the study's public registry record.
Cancer Connect · 800-622-8922 · clinicaltrials@cancer.wisc.edu
Always discuss trial participation with your own doctor first.
| University of Wisconsin Carbone Cancer Center | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05854498